# Hospital-exemption cell therapies at scale, backed by a shared registry

Source: https://onco.cc/ideas/idea-fund-hospital-exemption-registry/  
OnCo record `idea-fund-hospital-exemption-registry` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

European law already lets hospitals make advanced therapies for their own patients. Pair that with a shared outcomes registry so academic CAR-Ts and similar treatments can prove themselves without a commercial licence.

## Summary

The EU hospital exemption (and analogous national point-of-care manufacturing provisions in the UK, Spain, Japan and elsewhere) permits non-routine manufacture of advanced therapy medicinal products for individual patients under national oversight. It is used unevenly and generates little comparable evidence. The proposal is a harmonised framework: common quality standards, a mandatory prospective registry with standard outcome and toxicity capture, and a defined pathway by which registry evidence supports wider use or a conditional marketing authorisation. This lets academic products reach patients years earlier and creates a real-world evidence base for regulators.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A harmonised hospital-exemption registry across ten European centres captures outcomes for more than 90% of treated patients and supports at least one conditional authorisation or national reimbursement decision for an academic cell therapy within four years.
- Rationale: Spain's approval of ARI-0001 under hospital exemption shows the route can deliver a reimbursed academic CAR-T; the European Medicines Agency and national agencies have called for better evidence from exempted products. Registry-based approval pathways exist in Japan for regenerative medicine.
- Proposed test: Establish the registry and standards in a pilot consortium and evaluate data completeness, comparability with pivotal trial outcomes and regulatory uptake at three years.
- Maturity: early-clinical
- Actor: regulator

## Sources

- Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008): https://doi.org/10.1038/453840a

## Connected records

- ideas: [A public indemnity pool so universities can sponsor first-in-human cancer trials](https://onco.cc/ideas/idea-fund-academic-sponsor-indemnity-pool/), [Hospital-based CAR-T manufacturing at cost through a public network](https://onco.cc/ideas/idea-fund-public-car-t-manufacturing/), [Regional translational institutes with academic GMP suites and IND teams](https://onco.cc/ideas/idea-fund-translational-institutes-gmp/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/), [TIL therapy](https://onco.cc/technologies/til-therapy/)
- institutions: [Charité Universitätsmedizin Berlin](https://onco.cc/institutions/charite/), [Netherlands Cancer Institute (NKI-AvL)](https://onco.cc/institutions/nki/), [Vall d'Hebron University Hospital / VHIO](https://onco.cc/institutions/vall-dhebron/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)
- key papers: [Translational research: crossing the valley of death](https://onco.cc/key-papers/paper-butler-nature/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-hospital-exemption-registry.json